Mebeverine Hydrochloride Azure Pharmaceuticals

Mebeverine Hydrochloride, the active ingredient in Mebeverine Hydrochloride Azure Pharmaceuticals, is an antispasmodic presented as an oral tablet for systemic use. It is used to relieve abdominal cramps and pain associated with irritable bowel syndrome and other functional bowel disorders in adult patients.

GNH USA supplies Mebeverine Hydrochloride Azure Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. It ensures timely delivery to meet patient needs across multiple regions.

Mebeverine Hydrochloride is an antispasmodic that acts on the gastrointestinal smooth muscle to alleviate spasm‑related disorders. - Irritable bowel syndrome: reduces abdominal pain and cramping, improving bowel habit and quality of life. - Functional bowel disorders: eases discomfort and irregular motility associated with conditions such as spastic colon. - Chronic intestinal colic: diminishes recurrent colicky episodes by relaxing intestinal smooth muscle.

Mebeverine Hydrochloride may be associated with a range of adverse reactions, which are generally mild but can be serious in rare cases.

Common Side Effects: - Nausea: mild stomach upset. - Dry mouth: reduced salivation. - Headache: transient cranial discomfort. - Dizziness: light‑headed sensation. - Abdominal discomfort: mild cramping. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling. - Angioedema: rapid swelling of face, lips or throat. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before prescribing Mebeverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust use in patients with significant impairment. - Use with caution in the elderly: increased susceptibility to anticholinergic‑like effects. - Avoid in known hypersensitivity: discontinue if allergic signs appear. - Review concomitant anticholinergic medications: risk of additive dry‑mouth or constipation. - Monitor cardiac status: rare reports of arrhythmia warrant observation. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mebeverine Hydrochloride can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Other antispasmodic agents: additive smooth‑muscle relaxation leading to constipation. - Monoamine oxidase inhibitors: potential for exaggerated gastrointestinal effects.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., antihistamines, tricyclic antidepressants): monitor for excessive dry mouth or urinary retention. - Digoxin: observe for altered absorption due to changes in gut motility. - Antidepressants (SSRIs, SNRIs): watch for combined effects on gastrointestinal motility.